JPRN-jRCT2051200159招募中3 期
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Aerosolized JH509 in Hospitalized Adult Patients with Mild to Moderate COVID 19
Shoji Hashimoto0 个研究点目标入组 385 人开始时间: 2021年3月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 385
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Written informed consent has been obtained from the participants with the age of over 20 years at the time of signing the informed consent.
- •2.SARS-CoV-2 infection is diagnosed by RT-PCR within 72 hours before starting drug administration.
- •3.Less than 6 days from onset of COVID-19 symptoms to starting the administration of the investigational drug. The symptoms are defined as one or more of the following: fever (37.5 or higher), respiratory symptoms (cough, shortness of breath, chest pain, sore throat, running nose, nasal congestion, etc.), headache, malaise, abdominal pain, diarrhea, nausea, vomiting, loss of smell, loss of taste, or other COVID-19 symptoms defined by investigators or physicians.
- •4.Have at least one of the following findings.
- •Oxygen saturation (SpO2) measured by pulse oximeter is less than 96% but more than 93%.
- •Chest X-ray or CT scan shows pneumonia findings suggestive of COVID-19 infection
排除标准
- •1.History of hypersensitivity to interferon or Novaferon or any excipients of interferon or Novaferon.
- •2.Having received other antiviral treatments (Favipiravir, Remdesivir, interferon, etc.)
- •3.CTCAE Grade 3 or higher liver dysfunction (ALT / AST> 5ULN) or renal dysfunction (eGFR <30 mL / min / 1.73 m2)
- •4.Active infections or other medical conditions that contraindicate inhalation therapy
研究者
相似试验
尚未招募
3 期
Effectiveness of Bacillus Coagulans in improving appetite among patients admitted in hospitalCTRI/2018/11/016404Hindu Mission Hospital
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate HypertensioMen and women, 35-70 years old with mild to moderate Hypertension as classified by the British Hypertension Society (BHS) Guidelines - BHS-IV based on the following crietia of sitting blood pressure measured by spygomanography for patienst without diabetes or renal dysfunction:Grade 1 (mild): Systolic BP 140-159 mmHG and Diastolic BP of 90-99 mmHgGrade 2 (moderate): Systolic BP 160-179 mmHg and Diastolic BP 100-109 mmHgMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionMedDRA version: 9.1Level: PTClassification code 10020772Term: HypertensionMedDRA version: 9.1Level: PTClassification code 10042957Term: Systolic hypertensionMedDRA version: 9.1Level: PTClassification code 10012758Term: Diastolic hypertensionEUCTR2008-001001-41-GBProtherics Medicines Development Ltd, a BTG plc company
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) - 20060198low or intermediate-1 risk MDSMedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2007-007258-75-ITAmgen Inc.240
已完成
不适用
Effectiveness and safety of a herbal composition to improve Aging Male SymptomsCTRI/2019/02/017506aila Neutraceuticals Pvt Ltd
已完成
不适用
A study of Cordyceps Capsules as an Add-On Therapy in patients with moderate COVID 19 InfectioCTRI/2020/09/028131Ambrosia Food Farm Co